Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics is dedicated to creating transformative, next-generation cell therapies that have the potential to cure or improve the quality of life for patients with severe and life-threatening diseases.

Fate Therapeutics strives to be the leader in the development of programmed cellular therapeutics, and to bring life-saving treatments to patients as quickly and safely as possible.

Fate Therapeutics’ leadership and ground-breaking research have earned the company numerous awards, including the prestigious 2016 Bloomberg Longevity Game Changer Award, the 2014 Deloitte Technology Fast 500 award, and the 2014 USA Science & Engineering Festival Start-Up Challenge.